Recombinant adeno-associated viral (AAV) vectors of serotypes 6, 8, and 9 were characterized as tools for gene delivery to dopaminergic neurons in the substantia nigra for future gene therapeutic applications in Parkinson's disease. While vectors of all three serotypes transduced nigral dopaminergic neurons with equal efficiency when directly injected to the substantia nigra, AAV6 was clearly superior to AAV8 and AAV9 for retrograde transduction of nigral neurons after striatal delivery. For sequential transduction of nigral dopaminergic neurons, the combination of AAV9 with AAV6 proved to be more powerful than AAV8 with AAV6 or repeated AAV6 administration. Surprisingly, single-stranded viral genomes persisted in nigral dopaminergic neurons within cell bodies and axon terminals in the striatum, and intact assembled AAV capsid was enriched in nuclei of nigral neurons, 4 weeks after virus injections to the substantia nigra. 6-Hydroxydopamine (6-OHDA)–induced degeneration of dopaminergic neurons in the substantia nigra reduced the number of viral genomes in the striatum, in line with viral genome persistence in axon terminals. However, 6-OHDA–induced axonal degeneration did not induce any transsynaptic spread of AAV infection in the striatum. Therefore, the potential presence of viral particles in axons may not represent an important safety issue for AAV gene therapy applications in neurodegenerative diseases.
Get full access to this article
View all access options for this article.
References
1.
BartusR.T., BrownL., WilsonA.et al.2011a. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol Dis, 44:38–52.
2.
BartusR.T., HerzogC.D., ChuY.et al.2011b. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord, 26:27–36.
3.
BoutinS., MonteilhetV., VeronP.et al.2010. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther, 21:704–712.
4.
CearleyC.N., WolfeJ.H.2006. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther, 13:528–537.
5.
ChristineC.W., StarrP.A., LarsonP.S.et al.2009. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology, 73:1662–1669.
6.
CiesielskaA., MittermeyerG., HadaczekP.et al.2011. Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol Ther, 19:922–927.
7.
DenbyL., NicklinS.A., BakerAH. 2005. Adeno-associated virus (AAV)-7 and−8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation. Gene Ther, 12:1534–1538.
8.
Diaz-NidoJ.2010. NLX-P101, an adeno-associated virus gene therapy encoding glutamic acid decarboxylase, for the potential treatment of Parkinson's disease. Curr Opin Investig Drugs, 11:813–822.
9.
DouarA.M., PoulardK., StockholmD., DanosO.2001. Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J Virol, 75:1824–1833.
10.
DuringM.J., SamulskiR.J., ElsworthJ.D.et al.1998. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther, 5:820–827.
11.
DusonchetJ., BensadounJ.C., SchneiderB.L., AebischerP.2009. Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease. Neurobiol Dis, 35:32–41.
12.
EberlingJ.L., JagustW.J., ChristineC.W.et al.2008. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology, 70:1980–1983.
13.
EberlingJ.L., KellsA.P., PivirottoP.et al.2009. Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Hum Gene Ther, 20:511–518.
14.
EslamboliA., GeorgievskaB., RidleyR.M.et al.2005. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J Neurosci, 25:769–777.
15.
FitzsimonsH.L., RibanV., BlandR.J., WendelkenJ.L.et al.2010. Biodistribution and safety assessment of AAV2-GAD following intrasubthalamic injection in the rat. J Gene Med, 12:385–398.
GaoG., VandenbergheL.H., AlviraM.R.et al.2004. Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol, 78:6381–6388.
18.
GaoG.P., AlviraM.R., WangL.et al.2002. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A, 99:11854–11859.
19.
Gottfried-BlackmoreA., KaunznerU.W., IdoyagaJ.et al.2009. Acute in vivo exposure to interferon-gamma enables resident brain dendritic cells to become effective antigen presenting cells. Proc Natl Acad Sci U S A, 106:20918–20923.
20.
GrimmD., KayM.A., KleinschmidtJA. 2003. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther, 7:839–850.
21.
JacobsonS.G., AclandG.M., AguirreG.D.et al.2006. Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. Mol Ther, 13:1074–1084.
22.
JarrayaB., BouletS., RalphG.S.et al.2009. Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci Transl Med, 1:2ra4.
23.
JohnsonJ.S., SamulskiRJ. 2009. Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus. J Virol, 83:2632–2644.
24.
JohnsonJ.S., LiC., DiprimioN.et al.2010. Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction. J Virol, 84:8888–8902.
25.
KelkarS., DeB.P., GaoG.et al.2006. A common mechanism for cytoplasmic dynein-dependent microtubule binding shared among adeno-associated virus and adenovirus serotypes. J Virol, 80:7781–7785.
26.
KleinR.L., DaytonR.D., LeidenheimerN.J.et al.2006. Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. Mol Ther, 13:517–527.
27.
KleinR.L., DaytonR.D., TatomJ.B.et al.2008. Tau expression levels from various adeno-associated virus vector serotypes produce graded neurodegenerative disease states. Eur J Neurosci, 27:1615–1625.
28.
KordowerJ.H., EmborgM.E., BlochJ.et al.2000. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science, 290:767–773.
29.
KoreckaJ.A., SchoutenM., EggersR.et al.2011. Comparison of AAV serotypes for gene delivery to dopaminergic neurons in the substantia nigra. Viral Gene Therapy. XuK.InTech., 205–224.
30.
KuckD., KernA., KleinschmidtJA. 2007. Development of AAV serotype-specific ELISAs using novel monoclonal antibodies. J Virol Methods, 140:17–24.
31.
LawlorP.A., BlandR.J., MouravlevA.et al.2009. Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates. Mol Ther, 17:1692–1702.
32.
LuY., SongS.2009. Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors. Proc Natl Acad Sci U S A, 106:17158–17162.
33.
MarksW.J.Jr., BartusR.T., SiffertJ.et al.2010. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol, 9:1164–1172.
34.
MatsudaW., FurutaT., NakamuraK.C.et al.2009. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J Neurosci, 29:444–453.
35.
McFarlandN.R., LeeJ.S., HymanB.T., McLeanPJ. 2009. Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system. J Neurochem, 109:838–845.
36.
MuramatsuS., FujimotoK., KatoS.et al.2010. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther, 18:1731–1735.
37.
PedenC.S., BurgerC., MuzyczkaN., MandelRJ. 2004. Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol, 78:6344–6359.
38.
ProvostN., Le MeurG., WeberM.et al.2005. Biodistribution of raav vectors following intraocular administration: evidence for the presence and persistence of vector DNA in the optic nerve and in the brain. Mol Ther, 11:275–283.
39.
RutledgeE.A., HalbertC.L., RussellDW. 1998. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol, 72:309–319.
40.
SalegioE.A., SamaranchL., KellsA.P.et al.2013. Axonal transport of adeno-associated viral vectors is serotype-dependent. Gene Ther, 20:348–352.
41.
SamaranchL., SalegioE.A., San SebastianW.et al.2012. Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther, 23:382–389.
42.
SanftnerL.M., SuzukiB.M., DoroudchiM.M.et al.2004. Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV. Mol Ther, 9:403–409.
43.
SonntagF., BlekerS., LeuchsB.et al.2006. Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus. J Virol, 80:11040–11054.
44.
StiegerK., ColleM.A., DubreilL.et al.2008. Subretinal delivery of recombinant AAV serotype 8 vector in dogs results in gene transfer to neurons in the brain. Mol Ther, 16:916–923.
45.
StiegerK., SchroederJ., ProvostN.et al.2009. Detection of intact rAAV particles up to 6 years after successful gene transfer in the retina of dogs and primates. Mol Ther, 17:516–523.
46.
TowneC., SchneiderB.L., KieranD.et al.2010. Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6. Gene Ther, 17:141–146.
47.
TowneC., SetolaV., SchneiderB.L., AebischerP.2011. Neuroprotection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic benefit in fALS mice. Mol Ther, 19:274–283.
48.
VallesF., FiandacaM.S., EberlingJ.L.et al.2010. Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase I study for the treatment of Parkinson disease. Neurosurgery, 67:1377–1385.
49.
Van der PerrenA., ToelenJ., CarlonM.et al.2011. Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9. Gene Ther, 18:517–527.
50.
VandenbergheL.H., WangL., SomanathanS.et al.2006. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat Med, 12:967–971.
51.
WangL., MuramatsuS., LuY.et al.2002. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther, 9:381–389.
52.
YanZ., ZakR., LuxtonG.W.et al.2002. Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J Virol, 76:2043–2053.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
